Form 4: Former 10% Owner Sells Werewolf Therapeutics Shares

Ansbert Gadicke and affiliated entities, former 10% owners of Werewolf Therapeutics, Inc., sold nearly 200,000 shares of common stock over three days in December 2025.

Summary

• Ansbert Gadicke and several affiliated entities, collectively former 10% owners of Werewolf Therapeutics, Inc. (HOWL), reported sales of common stock.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan established on September 24, 2025.
• On December 2, 2025, 59,277 shares were sold at a weighted average price of $0.89 per share, with prices ranging from $0.852 to $0.9246.
• On December 3, 2025, 57,225 shares were sold at a weighted average price of $0.87 per share, with prices ranging from $0.82 to $0.9256.
• On December 4, 2025, 83,230 shares were sold at a weighted average price of $0.97 per share, with prices ranging from $0.92 to $1.0208.
• Following these transactions, the reporting persons collectively beneficially own 4,784,111 shares of Werewolf Therapeutics common stock indirectly through various MPM entities.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to significant share sales by a former 10% owner and affiliated entities, even if pre-planned. While 10b5-1 plans mitigate the immediate negative signal, the consistent selling at sub-$1 prices by a knowledgeable insider group can still weigh on investor confidence.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating a planned divestment rather than an immediate reaction to new negative information.

Negatives

• A former 10% owner and affiliated entities sold a significant number of shares (199,732 shares in total).
• The sales occurred at relatively low prices, ranging from $0.82 to $1.0208 per share.
• The continued reduction in ownership by a significant institutional investor group could be perceived negatively by the market.

Risks

• Increased selling pressure on Werewolf Therapeutics' stock due to ongoing divestment by a large former shareholder.
• Potential negative market sentiment if investors interpret the sales as a lack of confidence from a knowledgeable insider.

Future Outlook

NA

Industry Context

This filing reflects routine insider selling activity by a former significant shareholder in the biotechnology sector. While not directly indicative of broader industry trends, such sales can sometimes influence investor perception of individual companies within the sector, especially if the company is in a development stage.

Related Party Transactions

• Ansbert Gadicke, a former 10% owner, and entities he is associated with (MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC) are selling shares of Werewolf Therapeutics, Inc.
• The sales are considered related party transactions due to the reporting persons' significant historical ownership and ongoing affiliations.

Stakeholder Impact

• Shareholders: May experience increased selling pressure on the stock and potential negative sentiment due to the divestment by a former significant institutional holder.
• Company Management: May face questions regarding the implications of a former major investor reducing their stake.

Key Dates

Recommendation

While the sales by a former 10% owner are a negative signal, they were conducted under a pre-established 10b5-1 plan, which suggests a systematic divestment rather than an urgent reaction to new adverse information. Given the stock's current low price, a 'sell' recommendation might be premature without further fundamental analysis of Werewolf Therapeutics' pipeline and financial health. A 'hold' is appropriate to observe future developments and the impact of these sales.

Keywords

Werewolf Therapeutics, HOWL, SEC Form 4, Insider Sales, Ansbert Gadicke, MPM BioImpact, Stock Sales, Biotechnology, Oncology, Rule 10b5-1